Cardiology (all articles)
In patients hospitalized with COVID-19, right ventricular dilation or dysfunction was independently associated with a >2-fold increase in risk for mortality
10 Nov, 2020 | 09:36h | UTCCommentaries: Utility of RV Remodeling Over Risk Stratification in COVID-19 – American College of Cardiology AND Damage to heart’s right ventricle predicts a greater chance of death from COVID-19 – Weill Cornell Medical College
[Abstract Only] Randomized trial: In patients with persistent atrial fibrillation, treatment with catheter ablation + vein of Marshall ethanol infusion increased the likelihood of remaining free of AF, compared with catheter ablation alone
10 Nov, 2020 | 09:32h | UTCEffect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
VENUS: randomized trial of vein of Marshall ethanol added to catheter ablation of persistent AF. 13 years in the making… I hope to be faster next time! https://t.co/EfW8d4FOtu
— Miguel Valderrábano (@MiguelVldrbno) October 27, 2020
Systematic review: Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. “At present, there are no convincing data supporting any specific inotropic or vasodilating therapy to reduce mortality in hemodynamically unstable patients with CS or LCOS.”
10 Nov, 2020 | 09:30h | UTC
Cohort study: Nighttime high blood pressure phenotype linked to worse cardiovascular prognosis
10 Nov, 2020 | 09:29h | UTCCommentaries: People who experience high blood pressure while sleeping have increased risk of heart attacks, strokes – News Medical / American Heart Association AND Sleeptime BP Spikes Tied to Heart Troubles – Physician’s Weekly
[Abstract Only]: Randomized trial: Drug-coated balloons non-inferior to drug-eluting stents for small coronary artery disease
10 Nov, 2020 | 09:27h | UTCLong-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW Research—Long-term efficacy and safety of drug-coated balloons vs drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial https://t.co/Fmi4sZTSdU pic.twitter.com/UfznQp6gkh
— The Lancet (@TheLancet) October 20, 2020
JACC Focus Seminar: Advanced management of intermediate- and high-risk pulmonary embolism. Patients who deteriorate despite anticoagulation and those with high-risk PE should be considered for advanced therapies for pulmonary reperfusion, including systemic fibrinolysis, surgical embolectomy, and catheter-based therapies
9 Nov, 2020 | 01:20h | UTCAdvanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar – Journal of the American College of Cardiology (free for a limited period)
Podcast: Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar
Another study shows improved outcomes with dual antiplatelet therapy in the first weeks after an acute ischemic stroke or transient ischemic attack
9 Nov, 2020 | 01:16h | UTCRelated Guideline: Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ
JACC Review: Evaluation and management of patients with stable angina. Based on large clinical trials, medical therapy rather than revascularization is the initial management strategy for most patients
6 Nov, 2020 | 09:43h | UTCEvaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review – Journal of the American College of Cardiology (free for a limited period)
Summary: Evaluation and Management of Patients With Stable Angina – American College of Cardiology
High prevalence of pericardial involvement in college student-athletes recovering from COVID-19
5 Nov, 2020 | 09:08h | UTC
Commentary on Twitter
The heart and #COVID19 in 54 consecutive college athletes @WVUHealth w/ echo, MRIhttps://t.co/76DvMNaeBL @JACCJournals todayhttps://t.co/hMyY8cQNln @ppsengupta1 @BritoCardio
>1/3 had resolving pericarditis with mild-moderate covid or no symptoms; no myocarditis, no controls pic.twitter.com/GTj3JZxL26— Eric Topol (@EricTopol) November 5, 2020
Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more
5 Nov, 2020 | 08:58h | UTCClinical Management of Hyperkalemia – Mayo Clinic Proceedings
Association between industry payments to physicians and device selection in ICD implantation
4 Nov, 2020 | 09:40h | UTCAssociation Between Industry Payments to Physicians and Device Selection in ICD Implantation – JAMA (free for a limited period)
Editorial: Reconsidering Health Care Fraud and Abuse Laws (free for a limited period)
Commentary on Twitter
More evidence that payments from industry to physicians influence clinical decisions. Great paper led by @AmarMD99 in @YaleCardiology shows that patients most likely to receive ICD/CRD made by manufacturer that provided largest payments to their physician https://t.co/P1Hh2VAxur
— Joseph Ross (@jsross119) November 3, 2020
Perspective: Under ISCHEMIA’s long shadow, cardiologists ponder shifting guidelines, care
4 Nov, 2020 | 09:20h | UTCUnder ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care – TCTMD
Original study and commentaries: ISCHEMIA Trial: Initial Invasive vs. Conservative Strategy for Stable Coronary Disease AND ISCHEMIA Trial: Health-Status Outcomes with Initial Invasive vs. Conservative Care in Stable Coronary Disease
Review: A standardized and comprehensive approach to the management of cardiogenic shock
3 Nov, 2020 | 03:04h | UTCCommentary: New Review Urges Rethink of Cardiogenic Shock Care – TCTMD
Cohort study: Dietary inflammatory potential and risk of cardiovascular disease among men and women in the U.S.
3 Nov, 2020 | 03:05h | UTCCommentary: High Intake of Proinflammatory Foods Linked to CVD Risk – NEJM Journal Watch∗
The value of urinary sodium assessment in acute heart failure
3 Nov, 2020 | 03:02h | UTC
Five things clinicians and patients should question in Pediatric Cardiology
3 Nov, 2020 | 02:59h | UTCCommentary: Choosing Wisely: Practices to Question in Pediatric Cardiology – NEJM Journal Watch
See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
2 Nov, 2020 | 02:18h | UTC
AHA Scientific Statement: Prevention of complications in the cardiac intensive care unit
30 Oct, 2020 | 01:06h | UTCCommentary: New strategies suggested for critical heart care in the ICU – American Heart Association
Systematic review: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
29 Oct, 2020 | 08:57h | UTCSummary: PCSK9 inhibitors for prevention of cardiovascular disease – Cochrane Library
The ‘Ten Commandments’ in the new ESC Adult Congenital Heart Disease Guidelines
29 Oct, 2020 | 08:59h | UTCOriginal guideline and commentaries: 2020 ESC Guidelines for the management of adult congenital heart disease
Covid-19 and the athletic heart: Emerging perspectives on pathology, risks, and return to play
28 Oct, 2020 | 09:06h | UTCAuthor Interview: COVID-19 and the Athletic Heart: Emerging Perspectives on Pathology, Risks, and Return-to-Play
Commentary on Twitter
The heart in athletes with #Covid19.
Summary of knowledge base, which is limited, and recommendations for rest and return to play https://t.co/4JBVO7nvAE @JAMACardio— Eric Topol (@EricTopol) October 26, 2020
Observational Study: Ticagrelor, compared with clopidogrel, is not associated with better outcomes for patients with ACS treated with PCI
28 Oct, 2020 | 08:54h | UTCAssociation of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention – JAMA (free for a limited period)
Editorial: Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes – JAMA (free for a limited period)
Author Interview: Ticagrelor or Clopidogrel for Antiplatelet Therapy After Percutaneous Intervention for Acute Coronary Syndrome? – JAMA
Commentary on Twitter
In @JAMA_current, our article comparing ticagrelor and clopidogrel in patients with an acute coronary syndrome undergoing PCI. A remarkable international collaboration. Bottom line: more expensive med not better. https://t.co/SDAyI7Q1MV pic.twitter.com/RFmmy4qvrW
— Harlan Krumholz (@hmkyale) October 27, 2020
JACC Journal series gives in-depth look at COVID-19’s impact on the heart
27 Oct, 2020 | 09:49h | UTCNews release: Journal series gives in-depth look at COVID-19’s impact on the heart – American College of Cardiology
JACC Focus Seminar 1: Coronavirus and Cardiometabolic Syndrome
JACC Focus Seminar 2: Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes
JACC Focus Seminar 3: Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia
Observational study on the effectiveness of deep sedation for patients with intractable electrical storm refractory to antiarrhythmic drugs
27 Oct, 2020 | 09:34h | UTC
Commentary on Twitter
Effectiveness of deep sedation for patients with intractable electrical storm refractory to anti-arrhythmic drugs https://t.co/sY7R3rtdvF #AHAJournals @MartinsRaphae15 @EloiMarijon pic.twitter.com/7SD3epIUUi
— Circulation (@CircAHA) October 23, 2020
Perspective: COVID-19 can affect the heart
25 Oct, 2020 | 23:39h | UTCCOVID-19 can affect the heart – Science
Commentary from the author
What we know about the heart and #COVID19.
The problem is there's way too much we don't know.https://t.co/b1AR2of0gL@ScienceMagazine— Eric Topol (@EricTopol) October 25, 2020